622 related articles for article (PubMed ID: 34073952)
1. Assessing the Interactions of Statins with Human Adenylate Kinase Isoenzyme 1: Fluorescence and Enzyme Kinetic Studies.
Wujak M; Kozakiewicz A; Ciarkowska A; Loch JI; Barwiolek M; Sokolowska Z; Budny M; Wojtczak A
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073952
[TBL] [Abstract][Full Text] [Related]
2. Characterization of interactions of simvastatin, pravastatin, fluvastatin, and pitavastatin with bovine serum albumin: multiple spectroscopic and molecular docking.
Shi JH; Wang Q; Pan DQ; Liu TT; Jiang M
J Biomol Struct Dyn; 2017 May; 35(7):1529-1546. PubMed ID: 27484332
[TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Effects of Statins on A549 Nonsmall-Cell Lung Cancer Cell Line Lipids Using Fourier Transform Infrared Spectroscopy: Rosuvastatin Stands Out.
Aksoy HN; Ceylan C
Lipids; 2021 May; 56(3):289-299. PubMed ID: 33611813
[TBL] [Abstract][Full Text] [Related]
5. Interaction of statins with phospholipid bilayers studied by solid-state NMR spectroscopy.
Galiullina LF; Scheidt HA; Huster D; Aganov A; Klochkov V
Biochim Biophys Acta Biomembr; 2019 Mar; 1861(3):584-593. PubMed ID: 30578770
[TBL] [Abstract][Full Text] [Related]
6. Stability and removal of atorvastatin, rosuvastatin and simvastatin from wastewater.
Sulaiman S; Khamis M; Nir S; Lelario F; Scrano L; Bufo SA; Mecca G; Karaman R
Environ Technol; 2015; 36(24):3232-42. PubMed ID: 26047323
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of HMG CoA reductase inhibitors in experimentally-induced myocardial necrosis: Biochemical, morphological and histological studies.
Variya BC; Patel SS; Trivedi JI; Gandhi HP; Rathod SP
Eur J Pharmacol; 2015 Oct; 764():283-291. PubMed ID: 26169562
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, kinetic studies, and QSAR of dinucleoside polyphosphate derivatives as human AK1 inhibitors.
Kozakiewicz-Piekarz A; Grzegórska M; Ziemkiewicz K; Grab K; Baranowski MR; Zapadka M; Karpiel M; Kupcewicz B; Kowalska J; Wujak M
Bioorg Chem; 2024 Jul; 148():107432. PubMed ID: 38744169
[TBL] [Abstract][Full Text] [Related]
11. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
Xiao M; Li L; Zhu W; Wu F; Wu B
Expert Rev Clin Pharmacol; 2024 Mar; 17(3):255-261. PubMed ID: 38275183
[TBL] [Abstract][Full Text] [Related]
12. Binding thermodynamics of statins to HMG-CoA reductase.
Carbonell T; Freire E
Biochemistry; 2005 Sep; 44(35):11741-8. PubMed ID: 16128575
[TBL] [Abstract][Full Text] [Related]
13. Adenylate kinases of thermophiles
Ludwiczak A; Wujak M; Kozakiewicz A; Wojtczak A; Komoszyński M
Biochem Cell Biol; 2021 Aug; 99(4):499-507. PubMed ID: 34357813
[TBL] [Abstract][Full Text] [Related]
14. A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.
Tárraga-López PJ; Celada-Rodríguez A; Cerdán-Oliver M; Solera-Albero J; Ocaña-López JM; López-Cara MA; De Miguel-Clave J
Pharmacoeconomics; 2005; 23(3):275-87. PubMed ID: 15836008
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
[TBL] [Abstract][Full Text] [Related]
17. Statin-specific inhibition of Rab-GTPase regulates cPKC-mediated IKs internalization.
Ronzier E; Parks XX; Qudsi H; Lopes CM
Sci Rep; 2019 Nov; 9(1):17747. PubMed ID: 31780674
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin: new preparation. Opt for statins with evidence of efficacy on clinical outcome.
Prescrire Int; 2004 Aug; 13(72):132-4. PubMed ID: 15532136
[TBL] [Abstract][Full Text] [Related]
19. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F
Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
Igel M; Sudhop T; von Bergmann K
Eur J Clin Pharmacol; 2001 Aug; 57(5):357-64. PubMed ID: 11599653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
